US 11,833,189 B1
Sublingual Semaglutide-BPC 157 combination for weight loss
Suzanne Bentz, Scottsdale, AZ (US); Austin Lucht, Scottsdale, AZ (US); and Shelly Kocher, Scottsdale, AZ (US)
Assigned to RED MOUNTAIN MED SPA, LLC, Scottsdale, AZ (US)
Filed by Red Mountain Med Spa, LLC, Scottsdale, AZ (US)
Filed on Jul. 6, 2023, as Appl. No. 18/347,729.
Application 18/347,729 is a continuation of application No. 18/317,232, filed on May 15, 2023.
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/26 (2006.01); A61K 9/14 (2006.01); A61K 38/10 (2006.01); A61K 9/20 (2006.01); A61K 9/00 (2006.01)
CPC A61K 38/26 (2013.01) [A61K 9/006 (2013.01); A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2027 (2013.01); A61K 38/10 (2013.01)] 11 Claims
 
1. A sublingual Semaglutide composition comprising:
from about 0.10 wt. % to about 0.40 wt. % of Semaglutide or salt thereof;
from about 0.05 wt. % to about 0.15 wt. % of Body Protection Compound-157 (BPC-157) or salt thereof; and
a carrier comprising a mixture of untreated fumed silica, sodium stearyl fumarate, microcrystalline cellulose, colloidal silicon dioxide, mannitol, fructose, and crospovidone;
wherein the carrier comprises from about 0.1 wt. % to about 5 wt. % of sodium stearyl fumarate;
wherein the carrier comprises from about 0.5 wt. % to about 1 wt. % untreated fumed silica;
wherein the weight percentages are based on the total weight of the sublingual Semaglutide composition, and
wherein the sublingual Semaglutide composition is in the physical form of a loose powder amendable to tableting by compression in a tablet press.